drugset / Trial / NCT07418931
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung
Timeline
- Start
- 2026-05
- Primary completion
- 2028-05
- Completion
- 2030-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1200 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |